The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NEOSCAN: Phase II trial of neoadjuvant chemotherapy for resectable lung cancers with switch to chemo alternative in 18F-FDG PET nonresponders.
Mark G. Kris
No relevant relationships to disclose
Matthew David Hellmann
No relevant relationships to disclose
Jarushka Naidoo
No relevant relationships to disclose
Mark Dunphy
No relevant relationships to disclose
Camelia S. Sima
No relevant relationships to disclose
Robert J. Downey
No relevant relationships to disclose
William D. Travis
No relevant relationships to disclose
Christopher G. Azzoli
No relevant relationships to disclose
Jamie E. Chaft
Research Funding - Lilly